Dominant.

This cost-effective analysis is here to bring you another elusive dominating treatment strategy, this one for the systemic treatment of HER2+ breast cancer. Using enrollees of the KATHERINE trial as a backbone, 5 different neoadjuvant / adjuvant therapy combinations were compared using extrapolations from available clinical trial data. First of all, it’s notable that all 5 sported a price tag well above $400,000. Fortunately, the least expensive also bought the most quality-adjusted life years (QALYs), meaning it dominated in economic speak. TBL: Neoadjuvant paclitaxel + trastuzumab + pertuzumab coupled with adjuvant trastuzumab for patients with a complete response at surgery or dose-dense anthracycline/cyclophosphamide + T-DM1 for those with residual disease were the least expensive strategies (relatively speaking…) that also resulted in the most QALYs. | Kunst, JAMA Netw Open 2020

Comments

  1. Omg I Finally Got Helped  !! I'm so excited right now, I just have to share my testimony on this Forum.. The feeling of being loved takes away so much burden from our shoulders. I had all this but I made a big mistake when I cheated on my wife with another woman  and my wife left me for over 4 months after she found out..  I was lonely, sad and devastated. Luckily I was directed to a very powerful spell caster Dr Emu who helped me cast a spell of reconciliation on our Relationship and he brought back my wife and now she loves me far more than ever.. I'm so happy with life now. Thank you so much Dr Emu, kindly Contact  Dr Emu Today and get any kind of help you want.. Via Email emutemple@gmail.com or Call/WhatsApp +2347012841542

    ReplyDelete
  2. This is such a great resource that you are providing and you give it away for free. I love seeing blog that understand the value of providing a quality resource for free kubet

    ReplyDelete

Post a Comment

Popular Posts